Grünenthal Advances NaV 1.8 Inhibitor to Clinic, Challenging Opioid Dominance
Grünenthal has initiated clinical development for its proprietary NaV 1.8 inhibitor, a highly selective non-opioid analgesic candidate. This milestone positions the German pain specialist as a key contender in the race to develop potent, non-addictive treatments for acute and chronic pain.